{"id":"alecsat-cell-based-immunotherapy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4298070","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This involves using a patient's own immune cells to recognize and attack cancer cells.","oneSentence":"Cell-based immunotherapy targeting cancer cells","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:33:27.359Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of cancer"}]},"trialDetails":[{"nctId":"NCT01588769","phase":"PHASE1","title":"A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients","status":"COMPLETED","sponsor":"CytoVac A/S","startDate":"2011-08","conditions":"Glioblastoma Multiforme","enrollment":23},{"nctId":"NCT02060955","phase":"PHASE2","title":"Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan","status":"TERMINATED","sponsor":"CytoVac A/S","startDate":"2014-02","conditions":"Glioblastoma Multiforme","enrollment":25},{"nctId":"NCT01422850","phase":"PHASE1","title":"Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy","status":"COMPLETED","sponsor":"CytoVac A/S","startDate":"2011-08","conditions":"Hormone-refractory Prostate Cancer","enrollment":21},{"nctId":"NCT00891345","phase":"PHASE1","title":"Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy","status":"COMPLETED","sponsor":"CytoVac A/S","startDate":"2009-04","conditions":"Hormone-refractory Prostate Cancer","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ALECSAT cell based immunotherapy","genericName":"ALECSAT cell based immunotherapy","companyName":"CytoVac A/S","companyId":"cytovac-a-s","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cell-based immunotherapy targeting cancer cells Used for Treatment of cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}